Implications of T cell-mediated tumor killing genes for molecular heterogeneity and clinical stratification in lung adenocarcinoma  

作　　者：Tong Qiao Beining Yin Jun Liang Li Wei 

机构地区：[1]Department of Thoracic Surgery,Henan Provincial People's Hospital,Zhengzhou,Henan 450000,China [2]Reproductive Medicine Center,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450052,China [3]Department of Breast Surgery,Henan Provincial People's Hospital,Zhengzhou,Henan 450000,China

出　　处：《Genes & Diseases》2024年第4期39-41,共3页基因与疾病（英文）

摘　　要：Due to the profound heterogeneity exhibited amongst patients with lung adenocarcinoma(LUAD),considerable variances in clinical efficacy emerge.1 For the aims of precision medicine,a clinical instrument to delineate distinct disease phenotypes and anticipate susceptibility to intervention is imperative.Cellular cytotoxicity mediated through T lymphocytes constitutes a pivotal mechanism of anti-tumoral immunity and the foundation for cancer immunotherapy.?Numerous genes regulating the sensitivity of tumor cells to killing mediated by T lymphocytes(GSTKKs)are conducive to satisfying the aforesaid medical necessity.

关 键 词：CLINICAL MEDIATED ADENOCARCINOMA 

分 类 号：R734.2[医药卫生—肿瘤]